Abbott Laboratories (ABT) reported Q1 adjusted earnings Wednesday of $1.09 per diluted share, up from $0.98 a year earlier.
Analysts polled by FactSet expected $1.07.
Revenue for the quarter ended March 31 was $10.36 billion compared with $9.96 billion a year earlier.
Analysts surveyed by FactSet expected $10.41 billion.
For Q2, the company said it expects adjusted diluted earnings per share of $1.23 to $1.27. Analysts surveyed by FactSet expect $1.25.
Abbott reaffirmed its 2025 adjusted diluted earnings per share guidance of $5.05 to $5.25. Analysts surveyed by FactSet expect $5.15. The company also reiterated its annual organic sales growth to be 7.5% to 8.5%. Analysts polled by FactSet expect $44.40 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.